Trade Denali Therapeutics - DNLI CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.14 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 15.42 |
| Open | 15.19 |
| 1-Year Change | -2.19% |
| Day's Range | 14.98 - 15.73 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 15.42 | 0.91 | 6.27% | 14.51 | 15.61 | 14.51 |
| Apr 23, 2025 | 14.80 | -0.25 | -1.66% | 15.05 | 15.45 | 14.72 |
| Apr 22, 2025 | 14.54 | 1.39 | 10.57% | 13.15 | 14.60 | 13.15 |
| Apr 21, 2025 | 13.10 | 0.80 | 6.50% | 12.30 | 13.58 | 12.24 |
| Apr 17, 2025 | 12.69 | 0.24 | 1.93% | 12.45 | 12.81 | 12.24 |
| Apr 16, 2025 | 12.49 | -0.46 | -3.55% | 12.95 | 13.13 | 12.31 |
| Apr 15, 2025 | 13.10 | 0.03 | 0.23% | 13.07 | 13.57 | 12.95 |
| Apr 14, 2025 | 13.21 | 0.52 | 4.10% | 12.69 | 13.25 | 12.25 |
| Apr 11, 2025 | 12.64 | 0.28 | 2.27% | 12.36 | 12.66 | 11.95 |
| Apr 10, 2025 | 12.45 | -0.07 | -0.56% | 12.52 | 12.65 | 11.92 |
| Apr 9, 2025 | 12.79 | 1.82 | 16.59% | 10.97 | 13.21 | 10.73 |
| Apr 8, 2025 | 11.41 | -0.45 | -3.79% | 11.86 | 12.06 | 11.18 |
| Apr 7, 2025 | 11.53 | 0.33 | 2.95% | 11.20 | 11.78 | 10.51 |
| Apr 4, 2025 | 11.70 | -0.56 | -4.57% | 12.26 | 12.32 | 11.26 |
| Apr 3, 2025 | 12.73 | 0.08 | 0.63% | 12.65 | 13.25 | 12.36 |
| Apr 2, 2025 | 13.66 | 1.66 | 13.83% | 12.00 | 14.76 | 12.00 |
| Apr 1, 2025 | 12.22 | -1.09 | -8.19% | 13.31 | 13.62 | 11.99 |
| Mar 31, 2025 | 13.53 | -0.52 | -3.70% | 14.05 | 14.05 | 13.24 |
| Mar 28, 2025 | 14.72 | 0.68 | 4.84% | 14.04 | 14.77 | 13.96 |
| Mar 27, 2025 | 14.14 | 0.43 | 3.14% | 13.71 | 14.37 | 13.63 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Denali Therapeutics Company profile
About Denali Therapeutics Inc
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator program, enzyme transport vehicle: iduronate 2-sulfatase (ETV:IDS) program, receptor interacting serine/threonine protein kinase 1 (RIPK1) inhibitor program and second non-CNS penetrant RIPK1 inhibitor. The Company engineers its product candidates to cross the blood-brain barrier (BBB), and act directly in the brain. Its pipeline includes approximately 15 programs that are based on its TV technology, including the lead program ETV:IDS (DNL310). Its product pipeline includes DNL151, DNL593 (PTV:PGRN), DNL126 (ETV:SGSH), DNL788, DNL343, DNL758,
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Denali Therapeutics Inc revenues decreased 86% to $48.7M. Net loss totaled $290.6M vs. income of $71.1M. Revenues reflect Other collaboration revenue decrease of 96% to $4K. Net loss reflects Research & Development Expense - Balanci increase of 17% to $215.3M (expense), Stock-based Compensation in R&D increase of 73% to $50M (expense).
| Industry: | Bio Therapeutic Drugs |
161 Oyster Point Blvd
SOUTH SAN FRANCISCO
CALIFORNIA 94080-1910
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com